Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking treatments for neurodegenerative diseases, specifically focusing on Alzheimer's disease. Their mission is to detect and treat Alzheimer's disease, with a key focus on developing first-in-class medicines for individuals suffering from debilitating neurological conditions. Their primary drug candidate, Simufilam, is a novel small-molecule drug that seeks to stabilize a critical protein in the brain, potentially offering a new approach to treating Alzheimer's.

In addition to Simufilam, Cassava Sciences is also working on SavaDx, a blood-based diagnostic technology designed to detect Alzheimer's disease through a simple blood test. While SavaDx remains a lower priority program compared to Simufilam, it has the potential to revolutionize early detection and diagnosis of Alzheimer's, allowing for proactive intervention and potential treatment before the onset of severe symptoms.

Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience, with a mission to detect and treat Alzheimer's disease. They strive to develop first-in-class medicines for those with debilitating neurodegenerative conditions, including a blood test for early detection of Alzheimer's.

Cassava Sciences appears to cultivate a collaborative and driven culture focused on scientific advancement. The company emphasizes the complexity and importance of their work, highlighting their dedication to developing treatments for Alzheimer's disease. They express a strong commitment to collaboration, both internally among their teams and with external partners like academics and advisors. This suggests a work environment that values teamwork, intellectual curiosity, and a shared passion for improving human health.